Printer Friendly

MorphoSys widens scope of United States patent for HuCAL technology.

MorphoSys AG (Munich, Germany) announced that the United States Patent and Trademark Office has granted a new patent, which provides an extended protection of the MorphoSys core technology HuCAL (Human Combinatorial Antibody Library). The new patent (United States Patent 6,706,484) covers the method of obtaining an antigen specific antibody or an antibody fragment from the HuCAL library.

MorphoSys' antibody library is based on a proprietary phage display technology. This approach exploits the biological characteristic of bacteriophages - viruses that infect bacteria while being completely harmless for humans. Bacteriophages or derivatives thereof used in MorphoSys phage display libraries contain the genetic information for antibody fragments and display these fragments on their surface. Antibodies displayed in this way maintain their natural binding characteristics and structure, and can recognise a corresponding antigen. This proprietary selection process is covered by the newly obtained patent.

A first HuCAL patent, which is now complemented by the new patent, was issued by the United States Patent and Trademark Office in 2001. In February 2004, MorphoSys obtained an additional United States patent covering the genetic constitution of synthetic, fully modular human antibody libraries based on in silico consensus sequences. HuCAL patents have been granted in the United States, in Australia and at the European Patent Office. Furthermore MorphoSys has received several notifications of allowance for further patent applications in the United States To date, MorphoSys has eleven granted patents and more than 40 applications pending worldwide.

"This new patent further extends the protection of our proprietary core technology HuCAL in the United States. We will carry on with this process and strengthen our IP position on this important market for antibody-based products and services," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.

MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the company's proprietary Human Combinatorial Antibody Library (HuCAL) technology is used by researchers worldwide for human antibody generation. The company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Biogen Idec Inc. (Cambridge, Massachusetts/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (Wilmington, Delaware/USA), Centocor Inc. (Malvern, Pennsylvania/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Oridis Biomed GmbH (Graz/Austria), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA).

COPYRIGHT 2004 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Human Combinatorial Antibody Library
Publication:BIOTECH Patent News
Geographic Code:4EUGE
Date:Apr 1, 2004
Previous Article:Alliance and IL YANG announce a licensing, development and marketing agreement for Oxygent in Korea.
Next Article:Medifast diabetic product receives patent.

Related Articles
Crucell announces the issuance of major phage antibody patent.
MorphoSys issued patent for HuCAL antibody library.
GPC Biotech announces issuance of United States patent for detecting diseased cells.
MorphoSys wins final ruling in patent dispute with CAT.
Epicyte announces broad patent covering production of antibodies in plants.
Cambridge Antibody and Dyax amend antibody product agreement.
Cambridge Antibody announces therapeutic antibody licence agreement with Micromet.
MorphoSys and Novartis forge therapeutic antibody alliance.
MorphoSys and Boehringer Ingelheim start new antibody program.
Lux Biosciences gains exclusive worldwide license for ophthalmic polyarylate patent estate from Rutgers.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters